Resolve Biosciences raises $71M

Molecular cartography company Resolve Biosciences has raised $71 million in series B funding.

Resolve specializes in molecular cartography technology that allows researchers to view subcellular biology. The company’s platform is used by Stanford (Calif.) Medicine’s Department of Genetics, according to an Oct. 24 Resolve news release.

Resolve’s latest funding round brings the company’s total capital raised to more than $100 million. The company plans to use its series B capital to scale operations and accelerate product development.

The funding round was led by Patient Square Capital. 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars